Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 5-year second extension of a phase III randomized placebo-controlled odanacatib trial
2014-002587-33Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of odanacatib in osteoporosis, sponsored by Merck & Co. Primary endpoint: Percent change from baseline in total hip bone mineral density. Started Dec 2014; status: terminated.
02
Drugs
odanacatib
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2014-002587-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002587-33.